Physician profile

Michael J Ptasnik

Cardiovascular Disease · Lakewood, CO

NPI 1952307829

$6,187.43

in general payments reported to CMS, 2019-2025

39 companies · $578 in 2025

The $578 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,095.88
Consulting Fee$16.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $1,003.87 2019-2025 Eluvia, Watchman Access System
Medtronic, INC. $970.01 2021-2025 Hawkone, Micra, Aurora Ev-Icd Mri Surescan
Amgen INC. $694.46 2019-2025 Repatha, Repatha
Abiomed $339.74 2019-2021
E.R. Squibb & Sons, L.L.C. $323.08 2019-2025 Camzyos, Eliquis
Sanofi-Aventis U.S. LLC $285.89 2019-2024
Edwards Lifesciences Corporation $283.15 2019
Impulse Dynamics (USA) INC. $261.19 2022-2023 Optimizer
Baxter Healthcare $241.04 2022-2023 Hillrom - Carnation Ambulatory Monitor
Siemens Medical Solutions USA, INC. $180.39 2020
Pfizer INC. $178.27 2019-2025
Shockwave Medical, INC $160.11 2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Alnylam Pharmaceuticals INC. $129.48 2025 Amvuttra
Cardiovascular Systems INC. $116.46 2021
Astellas Pharma US INC $113.72 2020
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $105.10 2019-2020
Kowa Pharmaceuticals America, INC. $97.00 2019-2022
Boehringer Ingelheim Pharmaceuticals, INC. $77.93 2023-2024 Jardiance
Regeneron Healthcare Solutions, INC. $71.04 2019-2024 Evkeeza
Janssen Pharmaceuticals, INC $65.86 2019-2023 Xarelto
Merck Sharp & Dohme LLC $61.85 2021-2023 Verquvo
Kiniksa Pharmaceuticals, LTD. $61.56 2021-2022
Kiniksa Pharmaceuticals International, Plc $39.76 2024 Arcalyst
Esperion Therapeutics, INC. $35.37 2021-2022
Novo Nordisk INC $28.10 2025 Wegovy
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $27.55 2019-2021
Veryan Medical Incorporated $24.66 2022
Heartflow, INC. $23.36 2024
Amarin Pharma, INC. $22.53 2020
Astrazeneca Pharmaceuticals LP $22.05 2025 Wainua
Otsuka America Pharmaceutical, INC. $21.88 2019
Bayer Healthcare Pharmaceuticals INC. $21.04 2023
Scpharmaceuticals INC. $20.28 2025
Lexicon Pharmaceuticals, INC. $16.10 2023 Inpefa
Inspire Medical Systems, INC. $15.53 2023 Inspire
Atricure, INC. $14.82 2024
Ossur Americas, INC. $11.20 2024
Bardy Diagnostics, INC. $11.00 2020
Daiichi Sankyo INC. $11.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael J Ptasnik

$6,187.43

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $578 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/87765/michael-j-ptasnik

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.